An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors

被引:20
|
作者
Xie, Huiding [1 ,2 ,3 ]
Li, Yupeng [2 ,3 ]
Yu, Fang [2 ,3 ]
Xie, Xiaoguang [1 ]
Qiu, Kaixiong [2 ,3 ]
Fu, Jijun [2 ,3 ]
机构
[1] Yunnan Univ, Dept Chem, Kunming 650091, Peoples R China
[2] Kunming Med Univ, Dept Chem, Sch Pharmaceut Sci, Kunming 650500, Peoples R China
[3] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming 650500, Peoples R China
基金
中国国家自然科学基金;
关键词
imidazopyridine; B-Raf kinase; molecular docking; molecular dynamic simulation; THERAPEUTIC TARGET; CANCER; PROTEINS; MELANOMA; BRAF;
D O I
10.3390/ijms161126026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the recent cancer treatment, B-Raf kinase is one of key targets. Nowadays, a group of imidazopyridines as B-Raf kinase inhibitors have been reported. In order to investigate the interaction between this group of inhibitors and B-Raf kinase, molecular docking, molecular dynamic (MD) simulation and binding free energy (G(bind)) calculation were performed in this work. Molecular docking was carried out to identify the key residues in the binding site, and MD simulations were performed to determine the detail binding mode. The results obtained from MD simulation reveal that the binding site is stable during the MD simulations, and some hydrogen bonds (H-bonds) in MD simulations are different from H-bonds in the docking mode. Based on the obtained MD trajectories, G(bind) was computed by using Molecular Mechanics Generalized Born Surface Area (MM-GBSA), and the obtained energies are consistent with the activities. An energetic analysis reveals that both electrostatic and van der Waals contributions are important to G(bind), and the unfavorable polar solvation contribution results in the instability of the inhibitor with the lowest activity. These results are expected to understand the binding between B-Raf and imidazopyridines and provide some useful information to design potential B-Raf inhibitors.
引用
收藏
页码:27350 / 27361
页数:12
相关论文
共 50 条
  • [31] QSAR Study, Molecular Docking and Molecular Dynamic Simulation of Aurora Kinase Inhibitors Derived from Imidazo[4,5-b]pyridine Derivatives
    Tian, Yang-Yang
    Tong, Jian-Bo
    Liu, Yuan
    Tian, Yu
    MOLECULES, 2024, 29 (08):
  • [32] MEDI 368-Investigation of pyrazolo[1,5-a] pyrimidines as inhibitors of B-Raf kinase
    Torres, Nancy
    Berger, Dan M.
    Ciszewski, Greg
    Gopalsamy, Ariamala
    Kim, Kyung-Hee
    Levin, Jeremy I.
    Powelll, Dennis W.
    Buklan, Vlad Aron
    Collins, Karen
    Frommer, Eileen
    Wojciechowicz, Donald
    Mallon, Robert
    Hu, Yongbo
    Wilhelm, James
    Xu, Weixin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [33] A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
    Xie, Huiding
    Chen, Lijun
    Zhang, Jianqiang
    Xie, Xiaoguang
    Qiu, Kaixiong
    Fu, Jijun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (06): : 12307 - 12323
  • [34] B-Raf mutation: A key player in molecular biology of cancer
    Rahman, M. A.
    Salajegheh, A.
    Smith, R. A.
    Lam, A. K. -Y.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 95 (03) : 336 - 342
  • [35] The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors
    Tang, Jun
    Lackey, Karen E.
    Dickerson, Scott H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (01) : 66 - 70
  • [36] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase
    Takle, AK
    Brown, MJB
    Davies, S
    Dean, DK
    Francis, G
    Gaiba, A
    Hird, AW
    King, FD
    Lovell, PJ
    Naylor, A
    Reith, AD
    Steadman, JG
    Wilson, DM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (02) : 378 - 381
  • [37] Discovery of highly potent and selective type I B-Raf kinase inhibitors
    Wang, Xiaolun
    Berger, Dan M.
    Salaski, Edward J.
    Torres, Nancy
    Hu, Yongbo
    Levin, Jeremy I.
    Powell, Dennis
    Wojciechowicz, Donald
    Collins, Karen
    Frommer, Eileen
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6571 - 6574
  • [38] The synthesis of a novel inhibitor of B-Raf kinase
    Denni-Dischert, D
    Marterer, W
    Bänziger, M
    Yusuff, N
    Batt, D
    Ramsey, T
    Geng, P
    Michael, W
    Wang, RMB
    Taplin, F
    Versace, R
    Cesarz, D
    Perez, LB
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2006, 10 (01) : 70 - 77
  • [39] Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation
    Trakul, N
    Menard, RE
    Schade, GR
    Qian, ZH
    Rosner, MR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (26) : 24931 - 24940
  • [40] VEMURAFENIB B-raf Kinase Inhibitor Oncolytic
    Puzanov, I.
    Flaherty, K. T.
    Sosman, J. A.
    Grippo, J. F.
    Su, F.
    Nolop, K.
    Lee, R. J.
    Bollag, G.
    DRUGS OF THE FUTURE, 2011, 36 (03) : 191 - 199